Compare Oatly Group AB - ADR (OTLY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs Vertex Pharmaceuticals Incorporated — how do they compare? Oatly Group AB - ADR trades at $11.93 (market cap $330.93M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 387.3× Oatly Group AB - ADR's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oatly Group AB - ADR for 18 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| OTLY | VRTX | |
|---|---|---|
Market Cap | $330.93M | $128.16B |
Volume | 44,023 | 806,603 |
Sector | Consumer Staples | Health |
52-Week High | $15.91 | $557.96 |
52-Week Low | $8.03 | $407.37 |
Typical Hold Time | 18 Days | 120 Days |
Enterprise Value | $835.34M | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oatly (OTLY) trades at $10.38, down 1.24% today, with a mixed technical picture showing bearish moving averages but oversold RSI levels. The company continues to report revenue growth ($862M in 2025) but remains unprofitable with a -17.72% net margin. Recent Q2 2026 results showed a revenue beat and improved guidance, driving positive sentiment. Analyst consensus is divided with a $12.28 price target, while cash flow trends show gradual operational improvement despite negative net income.
The outlook remains challenging as Oatly works toward profitability amid high debt levels and negative cash flow. Investment opportunity exists if margin improvements continue and the company achieves positive EBITDA. Key risks include execution on cost controls, competitive pressures in plant-based beverages, and the sustainability of recent revenue growth momentum in a challenging consumer environment.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
